Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020440 (
hypercapnia
)
7,939
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cerebral hypoxia (10 min) followed immediately by ischemia (20 min) (H/I) impairs cerebrovasodilation in response to
hypercapnia
and hypotension in the newborn pig; exogenous
urokinase plasminogen activator
(
uPA
) potentiates this effect, whereas the blockade of endogenous
uPA
-mediated vasoactivity prevents it completely. This study investigated the role of integrin alpha(V)beta(3) in the
uPA
-mediated impairment of cerebrovasodilation after H/I in piglets equipped with a closed cranial window. Pial artery dilation induced by
hypercapnia
(Pco(2), 75 mmHg) and hypotension (mean arterial blood pressure, decreased by 45%) was blunted after H/I, reversed to vasconstriction in piglets treated with
uPA
(10(-7) M), a concentration observed in cerebrospinal fluid after H/I, but reverted to a dilation no different than preinsult in piglets administered an anti-alpha(V)beta(3) antibody (10 ng/ml) in addition to
uPA
(26 +/- 1, 9 +/- 1, -10 +/- 3, and 22 +/- 3% for
hypercapnia
before H/I, after H/I, after H/I with
uPA
, and after H/I with combined
uPA
and anti-alpha(V)beta(3) antibody, respectively). Responses to isoproterenol were unchanged after H/I and combined
uPA
and anti-alpha(V)beta(3) antibody. Similar results were obtained for the combined administration of
uPA
with the alpha(V)beta(3) antagonist Arg-Gly-Asp-d-Phe-Val and Arg-Gly-Asp-Ser, but not for the inactive analog Arg-Gly-Asp-Glu-Ser acetate. These data show that the activation of the integrin alpha(V)beta(3) contributes to the
uPA
-mediated impairment of pial artery dilation after H/I. These data suggest that the inhibition of
uPA
and integrin signaling may preserve cerebrohemodynamic control after H/I.
...
PMID:Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia. 1916 22